Cerebral Palsy Children Clinical Trial
Official title:
Effect of Nerve Growth Factor (Cerebrolysin) Therapy on Neurodevelopment, Sleep Pattern and Quality of Life in Children With Traumatic Brain Injury and Cerebral Palsy
Cerebral palsy (CP) is the most frequent cause of motor handicap among children. The
economic burden of CP in USA includes $1.18 billion in direct medical costs, $1.05 billion
in direct non-medical costs, and an additional $9.24 billion in indirect costs, for a total
cost of $11.5 billion or $921,000 average cost per person. Associated disabilities as mental
retardation, delayed speech development add psychological burden of the disease on the
family as well as economic burden.
Mental retardation is the major problem in children with cerebral palsy. Improving mental
development will have a positive effect on quality of life for the child and his family.
Treating associated impairments (mental retardation) with Cerebrolysin will improve mental
development and quality of life, and will decrease the economic burden in children with
cerebral palsy.
n/a
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05328466 -
Kinect Sensor in Cerebral Palsy Children Phase 2.2
|
N/A | |
| Withdrawn |
NCT05338229 -
Kinect Sensor in Cerebral Palsy Children: Phase 2.1
|
N/A |